Lupus & antiphospholipid syndrome
Diffuse alveolar haemorrhage in systemic lupus erythematosus: A multicentre retrospective study in Singapore
Authors' conclusion
The overall mortality of DAH in SLE patients remained high. There were no significant differences in patient demographics or clinical characteristics between the survivors and non-survivors. However, better survival appears to be associated with treatment with cyclophosphamide.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients with diffuse alveolar haemorrhage (DAH) hospitalised in 3 tertiary hospitals in Singapore, January 2007–October 2017
- Participants
- 35 patients
- Exposure
- Survivors vs non-survivors; survival by treatment group
- Outcome
- Overall mortality and survival
Methodological detailsmulticentre, 3 tertiary hospitals, medical records review
- Multicentre
- 3 tertiary hospitals
- Medical records review
Main finding
As reported in the abstract
- Overall mortality rate
- 40%
- Median survival time
- 162 days
- Remission
- 26 (74.3%)
- Median time to remission after DAH diagnosis, days (IQR 6-46)
- 12
- Mechanical ventilation required
- 22
- Median duration of mechanical ventilation
- 12 days
Observational data: associations, not effects.
Further findings
Survival by treatment
P = 0.0026
Demographics and clinical characteristics, survivors vs non-survivors
- No significant differences between survivors and non-survivors
Original publication
Diffuse alveolar haemorrhage in systemic lupus erythematosus: A multicentre retrospective study in Singapore. Lupus. Published 2 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →